Limb-Saving Showdown: ILI vs. ILP - Which Therapy Reigns Supreme for Melanoma?
"Discover the facts about Isolated Limb Infusion (ILI) and Isolated Limb Perfusion (ILP) for melanoma treatment. Uncover which procedure may be more effective and why patient selection is key."
When melanoma stubbornly recurs or spreads within a limb, simple treatments often fall short. Adequate disease control is crucial, as these metastases can cause pain, ulceration, and limited mobility, impacting daily life and social interactions. Elderly patients with recurrent disease often face additional challenges due to frailty and comorbidities.
Traditionally, isolated limb perfusion (ILP) has been a standard approach, but the minimally invasive alternative, isolated limb infusion (ILI), is gaining traction. Both aim to treat metastatic melanoma in a limb. Even with advancements in systemic therapies, ILI and ILP offer worthwhile, straightforward, single-treatment options.
These procedures address locally recurrent or in-transit metastatic melanoma. Both have acceptable, minor side effects and typically require only a short hospital stay. ILP boasts overall response rates of 64-96%, while ILI achieves 43-84%. Complete response rates are somewhat lower for ILI (27-44%) compared to ILP (25-69%). Although ILP appears to have better results, direct comparisons are problematic.
Regional Treatment for Limb Disease
Isolated limb infusion (ILI) is a minimally invasive procedure that delivers high-dose chemotherapy to an extremity affected by locally advanced or in-transit melanoma. Although ILI and hyperthermic isolated limb perfusion (HILP) are similar in principle, ILI is technically simpler and uses the hypoxic, acidotic environment of the isolated limb to potentiate melphalan with or without actinomycin-D. International multicenter research has evaluated ILI outcomes in patients with stage 3B or 3C melanoma.
From ILP to ILI
Since its introduction in the late 1950s, isolated limb perfusion (ILP) was described as a preferred treatment for locally advanced melanoma and sarcoma confined to a limb. In the early 1990s, Thompson and colleagues at the Sydney Melanoma Unit, now Melanoma Institute Australia, developed ILI as a simplified, minimally invasive alternative to ILP. Unlike ILP, ILI does not require an invasive surgical approach and uses radiological catheters with additional side holes near the limb vessels.
ILI vs. ILP: Why Patient Selection Matters More Than Procedure Type
Numerous studies have attempted to compare ILI and ILP outcomes, often favoring ILP due to higher complete response rates. However, such comparisons are misleading because the patient populations differ significantly. ILI is often chosen for older patients with more advanced disease, which inherently impacts outcomes.
- Patient Profile: ILI is generally offered to older, medically frail patients with advanced disease.
- Tolerability: The procedure is well-tolerated, making it suitable for patients who might not withstand ILP.
- Morbidity: ILI has markedly lower morbidity compared to ILP, reducing the risk of wound infections and other complications.
- Amputation Risk: Amputation is rare after melphalan ILI, but more frequently reported after ILP.
- Mortality: Post-procedural mortality has not been reported following ILI, but multiple studies have mentioned it following ILP.
- Systemic Side Effects: Systemic side effects are less frequent with ILI due to low-flow circulation, minimizing leakage of cytotoxic drugs.
Evolving Locoregional Evidence
A response regarding a systematic review and meta-analysis of locoregional treatments for in-transit melanoma clarified that the investigation was limited to locoregional therapies and did not formally analyze systemic agents. A separate technique report describes a 30-minute duration restriction for a percutaneous, high-flow, hyperthermic isolated limb perfusion approach. That report gives an approximate overall response rate of 73% and a complete response rate of 33%, while noting lower efficacy compared with HILP.
Variable Outcomes and Toxicity
Complete response rates after isolated limb infusion have varied considerably across reported experiences. One international multicenter study evaluated perioperative and long-term outcomes in patients with stage 3B or 3C melanoma who underwent first-time ILI between 1992 and 2018 at five Australian and four United States tertiary referral centers. Another study compared ILI outcomes for locally recurrent in-transit melanoma between the United States and Australia. These studies reflect the need to interpret efficacy, toxicity, morbidity, and quality-of-life outcomes in their clinical and geographic context.
Choosing Among Limb and Systemic Options
In-transit metastases develop in 10% of patients with high-risk melanoma, according to the cited study background. ILI and ILP are established therapies for in-transit metastases, but the ideal line of therapy has not been defined. Recent comparisons examine first-line ILI or ILP alongside immune checkpoint inhibitors and intralesional talimogene laherparepvec (TVEC).
The Future of Limb-Sparing Melanoma Treatment
In conclusion, while ILP might show slightly higher response rates, this is likely influenced by patient selection. It's essential to interpret these differences with caution, considering age, comorbidities, and disease stage. As systemic therapies evolve, ILI offers a less invasive option, aligning with future treatment combinations. Ultimately, a randomized controlled trial comparing ILI and ILP will provide a more accurate assessment of their respective values.
Patient Experience and Treatment Timing
Approximately 5% of patients with recurrent melanoma develop in-transit metastases, which can potentially be treated with ILP. Patient experiences with ILP have been studied because less is known about how people experience this treatment. A 2024 study reported that patients responded notably well when ILI was used as first-line therapy and also responded well when it was used as salvage therapy.